Product Information
LANSOPRAZOLE DR 15 MG ODT is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $1.9219 per EA under NDC 00093300893. Its NADAC has been published 343 times since Jul 18, 2018.
FDA first approved this application on Sep 21, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
15 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093300893
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LANSOPRAZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA208784FDA Approved
9/21/2017
TE Code
AB
On Market Since
3/8/2018
Pharmacological Classes
Price Statistics
The NADAC for LANSOPRAZOLE DR 15 MG ODT has been published 343 times since Jul 18, 2018, and over the history we have for it it has declined 82.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9219 per EA |
|---|---|
| All-time high | $10.6543 (Aug 22, 2018) |
| All-time low | $1.5080 (Apr 22, 2026) |
| 52-week high | $1.9219 |
| 52-week low | $1.5080 |
| Median price | $3.6404 |
| Average price | $4.2881 |
| Largest weekly change | +65.3% (Feb 21, 2024) |
| Weeks tracked | 343 |
| Tracking since | Jul 18, 2018 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lansoprazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Proton Pump Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LANSOPRAZOLE DR 15 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for LANSOPRAZOLE DR 15 MG ODT, manufactured by Teva Pharmaceuticals USA Inc., is $1.9219 per EA (NDC 00093300893), effective Sep 30, 2026.
How has the price of LANSOPRAZOLE DR 15 MG ODT changed over time?
Over the history we have for it, the NADAC for LANSOPRAZOLE DR 15 MG ODT has declined 82.0%. It has been tracked across 343 weekly CMS publications since Jul 18, 2018.
What are the highest and lowest recorded NADAC prices for LANSOPRAZOLE DR 15 MG ODT?
Since Jul 18, 2018, the NADAC for LANSOPRAZOLE DR 15 MG ODT has ranged from a low of $1.5080 (Apr 22, 2026) to a high of $10.6543 (Aug 22, 2018), with a median of $3.6404 per EA.
Are there cheaper alternatives to LANSOPRAZOLE DR 15 MG ODT?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LANSOPRAZOLE DR 15 MG ODT in a comparable dosage form, but none are currently priced below it.
Who manufactures LANSOPRAZOLE DR 15 MG ODT?
LANSOPRAZOLE DR 15 MG ODT (NDC 00093300893) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.